Cambrex Company Profile (NYSE:CBM)

About Cambrex (NYSE:CBM)

Cambrex logoCambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:CBM
  • CUSIP: 13201110
  • Web:
  • Market Cap: $1.7 billion
  • Outstanding Shares: 32,566,000
Average Prices:
  • 50 Day Moving Avg: $55.46
  • 200 Day Moving Avg: $53.11
  • 52 Week Range: $38.30 - $62.95
  • Trailing P/E Ratio: 19.93
  • Foreward P/E Ratio: 16.13
  • P/E Growth: 1.16
Sales & Book Value:
  • Annual Revenue: $500.61 million
  • Price / Sales: 3.40
  • Book Value: $13.22 per share
  • Price / Book: 3.95
  • EBIDTA: $161.83 million
  • Net Margins: 16.65%
  • Return on Equity: 24.53%
  • Return on Assets: 15.94%
  • Current Ratio: 3.38%
  • Quick Ratio: 2.09%
  • Average Volume: 330,024 shs.
  • Beta: 1.95
  • Short Ratio: 6.76

Frequently Asked Questions for Cambrex (NYSE:CBM)

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) announced its quarterly earnings results on Thursday, May, 4th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.51 by $0.17. The firm earned $105.01 million during the quarter, compared to the consensus estimate of $99.05 million. Cambrex had a net margin of 16.65% and a return on equity of 24.53%. The business's quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the firm earned $0.50 EPS. View Cambrex's Earnings History.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY17 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $2.94-3.06 for the period, compared to the Thomson Reuters consensus estimate of $3.01. The company issued revenue guidance of +7-11% to ~$524.62-544.233 million, compared to the consensus revenue estimate of $535.27 million.

Where is Cambrex's stock going? Where will Cambrex's stock price be in 2017?

3 brokers have issued 12-month target prices for Cambrex's shares. Their predictions range from $61.00 to $70.00. On average, they anticipate Cambrex's share price to reach $65.67 in the next year. View Analyst Ratings for Cambrex.

Who are some of Cambrex's key competitors?

Who owns Cambrex stock?

Cambrex's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.29%), Vanguard Group Inc. (9.64%), William Blair Investment Management LLC (6.21%), Bank of New York Mellon Corp (5.09%), Dimensional Fund Advisors LP (4.05%) and Wells Fargo & Company MN (4.06%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix, Jr, Louis J Grabowsky, Peter G Tombros, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.

Who sold Cambrex stock? Who is selling Cambrex stock?

Cambrex's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Columbia Wanger Asset Management LLC, Thomson Horstmann & Bryant Inc., William Blair Investment Management LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Ameriprise Financial Inc. and JPMorgan Chase & Co.. Company insiders that have sold Cambrex stock in the last year include Gregory Sargen, Shawn Cavanagh, Steven M Klosk and William B Korb. View Insider Buying and Selling for Cambrex.

Who bought Cambrex stock? Who is buying Cambrex stock?

Cambrex's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Neumeier Poma Investment Counsel LLC, OppenheimerFunds Inc., Renaissance Technologies LLC, Vanguard Group Inc., Opus Capital Group LLC and Congress Asset Management Co. MA. View Insider Buying and Selling for Cambrex.

How do I buy Cambrex stock?

Shares of Cambrex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cambrex stock cost?

One share of Cambrex stock can currently be purchased for approximately $52.25.

Analyst Ratings

Consensus Ratings for Cambrex (NYSE:CBM) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $65.67 (25.68% upside)

Analysts' Ratings History for Cambrex (NYSE:CBM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/6/2017StephensSet Price TargetBuy$61.00N/AView Rating Details
2/6/2017Craig HallumSet Price TargetBuy$70.00N/AView Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 -> $66.00N/AView Rating Details
2/11/2016Singular ResearchLower Price TargetBuy$63.00 -> $60.00N/AView Rating Details
2/1/2016SidotiInitiated CoverageBuy$60.00N/AView Rating Details
7/31/2015Longbow ResearchReiterated RatingBuy$48.00 -> $60.00N/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for Cambrex (NYSE:CBM)
Earnings by Quarter for Cambrex (NYSE:CBM)
Earnings History by Quarter for Cambrex (NYSE:CBM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017$0.51$0.68$99.05 million$105.01 millionViewListenView Earnings Details
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.53$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.60$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.29$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.32$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.05$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cambrex (NYSE:CBM)
2017 EPS Consensus Estimate: $2.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.48$0.51$0.50
Q2 20172$0.71$0.74$0.73
Q3 20172$0.46$0.52$0.49
Q4 20172$1.17$1.20$1.19
Q1 20181$0.58$0.58$0.58
(Data provided by Zacks Investment Research)


Dividend History for Cambrex (NYSE:CBM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cambrex (NYSE:CBM)
Insider Ownership Percentage: 2.63%
Institutional Ownership Percentage: 98.23%
Insider Trades by Quarter for Cambrex (NYSE:CBM)
Institutional Ownership by Quarter for Cambrex (NYSE:CBM)
Insider Trades by Quarter for Cambrex (NYSE:CBM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Steven M KloskCEOSell12,000$58.20$698,400.00View SEC Filing  
4/3/2017Steven M KloskCEOSell12,000$54.58$654,960.00View SEC Filing  
3/1/2017Steven M KloskCEOSell12,000$56.70$680,400.00View SEC Filing  
2/27/2017Shawn CavanaghCOOSell19,620$55.95$1,097,739.00View SEC Filing  
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.00View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.00View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.60View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.00View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.00View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.00View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.74View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.00View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.00View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.00View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.52View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.46View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.00View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.32View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.80View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.00View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.00View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.00View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.00View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.00View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.00View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cambrex (NYSE:CBM)
Latest Headlines for Cambrex (NYSE:CBM)
DateHeadline logoETFs with exposure to Cambrex Corp. : May 22, 2017 - May 22 at 4:04 PM logoCleantech Building Materials: AMENDMENT OF LOAN FACILITY, DEBT CONVERSION AND ISSUE OF NEW SHARES - May 19 at 8:52 AM logoCleantech Building Materials: Reduction in Share Capital - May 17 at 11:44 AM logoCambrex to Present at the 2017 UBS Global Healthcare Conference - May 15 at 3:53 PM logoCambrex Corp. – Value Analysis (NYSE:CBM) : May 11, 2017 - May 11 at 9:47 PM logoCambrex Co. (CBM) Upgraded at Zacks Investment Research - May 11 at 6:34 PM logoCambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : May 9, 2017 - May 9 at 4:10 PM logoCambrex Co. (CBM) to Post Q2 2017 Earnings of $0.74 Per Share, First Analysis Forecasts - May 9 at 7:26 AM logoZacks: Brokerages Expect Cambrex Co. (CBM) Will Post Earnings of $0.78 Per Share - May 5 at 6:10 PM logoCambrex Co. (CBM) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS - May 4 at 10:44 PM logoEdited Transcript of CBM earnings conference call or presentation 4-May-17 12:30pm GMT - May 4 at 9:20 PM logoCambrex Reports First Quarter 2017 Financial Results - May 4 at 4:19 PM logoCambrex Co. (CBM) Releases FY17 Earnings Guidance - May 4 at 11:17 AM logoCambrex posts 1Q profit - May 4 at 7:31 AM logoCambrex (CBM) Earns Daily News Sentiment Score of 0.37 - May 3 at 12:54 AM logoInsider Selling: Cambrex Co. (CBM) CEO Sells 12,000 Shares of Stock - May 2 at 9:26 PM logoCambrex Co. (CBM) Set to Announce Earnings on Thursday - May 2 at 1:21 PM logoCambrex to Announce First Quarter 2017 Financial Results on May 4, 2017 - May 1 at 4:10 PM logoPositive Media Coverage Likely to Impact Cambrex (CBM) Stock Price - April 27 at 2:28 PM logoCleantech Building Materials: General Meeting - April 26 at 3:08 PM logoSomewhat Favorable News Coverage Very Likely to Affect Cambrex (CBM) Share Price - April 24 at 8:08 PM logoCleantech Building Materials: Settlement through VP Securities A/S - April 21 at 4:17 PM logoCleantech Building Materials: Issue of Shares - April 19 at 1:01 PM logoPositive Media Coverage Very Unlikely to Effect Cambrex (CBM) Share Price - April 13 at 5:51 PM logoPosting of Circular to Shareholders - April 7 at 4:10 PM logoSteven M. Klosk Sells 12,000 Shares of Cambrex Co. (CBM) Stock - April 3 at 7:58 PM logoCleantech Building Materials: Annual Results to 31 December 2016 - March 29 at 4:34 PM logoDoes Cambrex Offer a Great Value Buying Opportunity Right Now? - March 17 at 4:45 PM logoCambrex (CBM) Presents at RBC Capital Markets Global Healthcare Conference 2017-Slideshow - February 22 at 9:21 PM logoCleantech Building Materials: Auditor Resignation and Appointment - February 21 at 1:50 PM logoCambrex: A Pure Growth Play - Seeking Alpha - February 16 at 4:14 PM logoCambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conference - February 16 at 9:01 AM logoCAMBREX CORP Financials - February 8 at 4:26 PM logo6:48 am Cambrex beats by $0.19, beats on revs; issues 2017 guidance - February 5 at 4:09 PM logoEdited Transcript of CBM earnings conference call or presentation 3-Feb-17 1:30pm GMT - February 3 at 9:25 PM logoCambrex Q4 Profit Tops Estimates; Sales Up 14% - Quick Facts - February 3 at 4:23 PM logoCambrex Corporation (CBM) Jumps on Earnings Estimate - February 3 at 4:23 PM logoCambrex Corp. (CBM) Has Surged To A New High On Strong Q4 Results - February 3 at 4:23 PM logoQ4 2016 Cambrex Corp Earnings Release - Before Market Open - February 3 at 4:23 PM logoCambrex Reports Fourth Quarter and Full Year 2016 Financial Results - February 3 at 8:25 AM logoCambrex beats by $0.18, beats on revenue - February 3 at 6:58 AM logoCambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017 - February 1 at 4:27 PM logoCleantech Building Materials: LOAN CONVERSION AND ISSUE OF NEW SHARES - January 27 at 5:25 PM logoAmgen's Repatha Wins Over Sanofi & Regeneron's Praluent - January 6 at 9:33 PM


Cambrex (CBM) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff